Trials / Completed
CompletedNCT01438554
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib | |
| DRUG | GSK1120212 |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2016-04-01
- Completion
- 2018-08-01
- First posted
- 2011-09-22
- Last updated
- 2018-08-29
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01438554. Inclusion in this directory is not an endorsement.